Bubs Australia forecasts full US FDA market access approval by October 2025

The Market Herald09-17

Infant formula powder player Bubs Australia (ASX:BUB) has predicted it will have the US FDA’s full blessings in just over a year’s time. You may remember the stock causing a lot of hubbub during the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468803623?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-17 07:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468803623","market":"us","top_or_hot":-1,"title":"Bubs Australia forecasts full US FDA market access approval by October 2025","media":"The Market Herald","content":"<div>\n<p>Infant formula powder player Bubs Australia (ASX:BUB) has predicted it will have the US FDA’s full blessings in just over a year’s time.\nYou may remember the stock causing a lot of hubbub during the ...</p>\n\n<a href=\"https://themarketonline.com.au/bubs-australia-forecasts-full-us-fda-market-access-approval-by-october-2025-2024-09-17/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bubs Australia forecasts full US FDA market access approval by October 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBubs Australia forecasts full US FDA market access approval by October 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-17 07:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/bubs-australia-forecasts-full-us-fda-market-access-approval-by-october-2025-2024-09-17/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Infant formula powder player Bubs Australia (ASX:BUB) has predicted it will have the US FDA’s full blessings in just over a year’s time.\nYou may remember the stock causing a lot of hubbub during the ...</p>\n\n<a href=\"https://themarketonline.com.au/bubs-australia-forecasts-full-us-fda-market-access-approval-by-october-2025-2024-09-17/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7141","symbol_name":"包装食品与肉类","start_time":0,"source_url":"https://themarketonline.com.au/bubs-australia-forecasts-full-us-fda-market-access-approval-by-october-2025-2024-09-17/","article_id":"2468803623","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468803623","pubTimestamp":1726530720,"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"Infant formula powder player Bubs Australia  has predicted it will have the US FDA’s full blessings in just over a year’s time.You may remember the stock causing a lot of hubbub during the COVID years when a baby formula shortage in the United States caused eyes to start scouring the local market for value.Bubs and A2 Milk were widely the most popular stocks attached to that proposition.Now, the company has seen its 400th patient enrolled in an ongoing infant powder trial to establish safety and benefits of the product. That study comes on the back of a 2022 regulatory directive from the FDA.“Bubs was the first company to offer assistance from abroad, participating in the US government’s ‘Operation Fly Formula’ program, and Bubs was the 2nd company in the world to be granted ‘temporary enforcement discretion’ .“Bubs will transition from ‘temporary enforcement discretion’ to permanent market access, upon FDA approval, expected in October 2025,” the company wrote on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7141":"包装食品与肉类","XJO.AU":"标普/澳交所 200指数","BUB.AU":"BUBS AUSTRALIA LTD","XKO.AU":"标普/澳交所 300指数","BK7505":"食品股","XAO.AU":"标普/澳交所 普通股指数","BK7509":"中概股"},"translate_title":"Bubs Australia预测美国FDA将于2025年10月全面批准市场准入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUB.AU":1,"XAO.AU":1,"XJO.AU":1,"XKO.AU":1},"content_text":"Infant formula powder player Bubs Australia (ASX:BUB) has predicted it will have the US FDA’s full blessings in just over a year’s time.\nYou may remember the stock causing a lot of hubbub during the COVID years when a baby formula shortage in the United States caused eyes to start scouring the local market for value. \nBubs and A2 Milk were widely the most popular stocks attached to that proposition.\nNow, the company has seen its 400th patient enrolled in an ongoing infant powder trial to establish safety and benefits of the product. That study comes on the back of a 2022 regulatory directive from the FDA.\n“Bubs first began importing its infant formulas into the United States in May 2022 as a response to the infant formula shortage that year,” the company wrote on Tuesday.\n“Bubs was the first company to offer assistance from abroad, participating in the US government’s ‘Operation Fly Formula’ program, and Bubs was the 2nd company in the world to be granted ‘temporary enforcement discretion’ .\n“Bubs will transition from ‘temporary enforcement discretion’ to permanent market access, upon FDA approval, expected in October 2025,” the company wrote on Tuesday.\nThe clinical trial is US-wide and referred to as a “Growth, Tolerance and Safety” study. That the company has clocked its 400th participant after launching 13 months ago Bubs said on Tuesday is testament to its acumen.\nBUB last traded at 12cps.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468803623"}